Acumen Pharmaceuticals nominated ACU301 and ACU401 as development candidates combining its amyloid beta oligomer antibodies with JCR Pharmaceuticals' blood-brain barrier penetration technology. The company plans to submit an IND application in mid-2027, expanding its pipeline with a differentiated bispecific antibody approach for Alzheimer's disease.